USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/4450
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRevenco, Valeriu
dc.contributor.authorOchişor, Viorica
dc.date.accessioned2019-06-25T16:01:44Z-
dc.date.available2019-06-25T16:01:44Z-
dc.date.issued2011
dc.identifier.citationREVENCO, Valeriu, OCHIŞOR, Viorica. Influienţa ß- adrenoblocantului selectiv nebivolol asupra metabolismului lipidic la pacienţii cu sindrom metabolic. In: Anale ştiinţifice ale USMF “Nicolae Testemiţanu”. Ed. a 12-a. Chişinau: СEP Medicina, 2011, Vol. 3: Probleme actuale în medicina internă, pp. 13-17.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/4450-
dc.descriptionCatedra Cardiologie, USMF „Nicolae Testemiţanu”en_US
dc.description.abstractA study of a group of 63 patients with metabolic syndrome, with average age of 49±0,6 years, was carried out. The control group included 56 patients with the same age as the study group with arterial hypertension, without metabolic syndrome. The criterion of inclusion in the study group was arterial hypertension I-II degree associated with obesity. The administration of the long term treatment with Nebivolol 5 mg in patients with arterial hypertension and obesity hasn’t negatively influenced the lipid spectrum of these patients. But in patients with metabolic syndrome it improves the lipid spectrum state with significant reducion of triglyceride, total cholesterol and LDL-cholesterol values. A fost efectuat studiul unui lot de 63 pacienţi cu sindrom metabolic cu vîrsta medie 49±0,6 ani, lotul de control fiind constituit din 56 pacienţi de aceeaşi vîrstă cu hipertensiune arterială fără sindrom metabolic. Criteriu de includere în grupul de cercetare a fost hipertensiunea arterială de gradul I-II în asociere cu obezitatea. Administrarea tratamentului de durată cu Nebivolol 5mg pacienţilor hipertensivi obezi nu a influienţat negativ starea spectrului lipidic la pacienţii cu hipertensiune arterială şi obezitate. Dar la pacienţii cu sindrom metabolic ameliorează starea spectrului lipidic prin reducerea semnificativă a valorilor trigliceridelor, colesterolului total şi LDL-colesterolului.en_US
dc.language.isoroen_US
dc.publisherCEP "Medicina"en_US
dc.titleInfluienţa ß- adrenoblocantului selectiv nebivolol asupra metabolismului lipidic la pacienţii cu sindrom metabolicen_US
dc.title.alternativeThe influence of β adrenobloker Nebivolol on lipid spectrum in patients with metabolic syndromeen_US
dc.typeArticleen_US
Appears in Collections:Cardiologie

Files in This Item:
File Description SizeFormat 
INFLUIENTA_ss_ADRENOBLOCANTULUI_SELECTIV_NEBIVOLOL_ASUPRA.pdf193.12 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback